Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Titel:
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Auteur:
Larkin, James Weber, Jeffrey Del Vecchio, Michele Gogas, Helen Arance, Ana M. Dalle, Stephane Cowey, C. Lance Schenker, Michael Grob, Jean-Jacques Chiarion-Sileni, Vanna Márquez-Rodas, Iván Butler, Marcus O. Di Giacomo, Anna Marie Middleton, Mark R. De la Cruz-Merino, Luis Arenberger, Petr Atkinson, Victoria Hill, Andrew Fecher, Leslie A. Millward, Michael Khushalani, Nikhil I. Queirolo, Paola Long, Georgina V. Lobo, Maurice Askelson, Margarita Ascierto, Paolo A. Mandalá, Mario